local coverage determination
CMS Contractor Novitas Rescinds Noncoverage Decision for Cancer Genetic Tests
The original decision rescinded coverage for tests from Castle Biosciences, Pacific Edge Diagnostics, Interpace Biosciences, Abbott, Clinical Genomics, and the University of Pittsburgh Medical Center.
Local Coverage Determinations Roundup: Castle Biosciences
Multiple Medicare Administrative Contractors aligned their non-coverage decisions for Castle Biosciences' DecisionDx-SCC test.
CMS Contractor Novitas Rescinds Coverage for Multiple Cancer Genetic Tests
Novitas reviewed, analyzed, and published literature for a variety of genetic oncology tests and highlighted several that it claims are not medically reasonable or necessary.
Interpace Biosciences to Stop Offering Pancreatic Cancer Test After Losing CMS Reimbursement
Novitas said in its coverage determination that the test has not demonstrated incremental clinical value in the prognosis of pancreatic cysts and associated cancer.
CMS Contractor Proposes Noncoverage of Castle Biosciences Skin Cancer Test
The contractor said that the test has not yet demonstrated definitive value above the combination of available clinical, pathological, and staging criteria in accurate risk stratification.